Transcode Therapeutics P/CF

P/CF (Price-to-Cash-Flow Ratio) of Transcode Therapeutics is -0.64 in 2026.

P/CF (Price-to-Cash-Flow Ratio) of Transcode Therapeutics changed from -0.47 to -0.64, representing a 35.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Transcode Therapeutics with sector peers and the industry average to assess whether it is attractive.